Clinical trial
Phase II Trial of Allovectin-7® for Head and Neck Cancer
NCT00050388 · Vical, Industry · Completed
Key facts
| NCT number | NCT00050388 |
|---|---|
| Title | Phase II Trial of Allovectin-7® for Head and Neck Cancer |
| Official title | Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx |
| Lead sponsor | Vical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck |
| Intervention type | Genetic |
| Interventions | Allovectin-7® |
| Completion | Jun 1, 2002 |
| First posted | Dec 9, 2002 |
| Last update posted | Jun 24, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: